Bone cancer is a group of malignancies that affects the patient’s bones , while primary cancers (those that originated in the bones and do not result from cancer metastases to other tissues) are relatively rare and are mainly detected in children . About 52 thousand new cases of this disease are registered annually. Unfortunately, until now, the means for its treatment are very limited:
mainly chemotherapy and radiation therapy are used , as well as surgical interventions up to amputation . Despite all of this, the five-year survival rate in patients with bone cancer is only 42%, mainly due to rapid tumor progression and extensive hematogenous metastases, primarily affecting the lungs and brain . Researchers from the University of East Anglia (UK) have proposed a new method of treatment:
the CADD522 drug they developed blocked the RUNX2 gene associated with the spread of cancer metastases and increased survival by 50% in laboratory mice implanted with human bone cancer. Unlike traditional treatments such as chemotherapy, the new drug is less harmful to the body and does not cause toxic side effects such as hair loss or digestive problems. In addition, the work of the RUNX2 gene is not required by normal cells that have not yet turned into cancer cells, so a healthy person’s intake of CADD522 will pass without any special consequences for the body. The study is published in the Journal of Bone Oncology . Video links:
#bone cancer #cancer #cure #chemotherapy #amputation #scientific study #health #cancer #medicine
